Modifies provisions relating to health care providers
SB 292 is a broad health care provider bill that revises several Missouri statutes governing controlled substances, physician licensure, and hospital pharmacy operations. A large portion of the bill updates definitions in the controlled substances chapter, including terms such as acute pain, industrial hemp, marijuana, synthetic cannabinoid, opioid, methamphetamine precursor drug, drug paraphernalia, and imitation controlled substance. It also revises rules for registration, prescribing, dispensing, and possession of controlled substances, including limits and exceptions for practitioners, advanced practice registered nurses, veterinarians, and hospitals.
The bill also changes physician licensing requirements by replacing older education language with modern accreditation-based standards, criminal background checks, and documentation of postgraduate training. It allows the medical board to consider prior licenses and disciplinary history, and it creates a waiver path for certain out-of-state physicians and applicants with unaccredited subspecialty training in accredited teaching hospitals. In addition, the bill updates hospital pharmacy law by clarifying the division of authority between the Department of Health and Senior Services and the Missouri Board of Pharmacy, authorizing medication orders in hospitals and hospital clinics, and establishing advisory committee input on joint rulemaking.
SB 292 would amend sections in chapters 195, 334, and 338 of the Revised Statutes of Missouri, affecting controlled substance regulation, physician licensure, and hospital pharmacy oversight. It would modernize statutory definitions and prescribing rules, reinforce registration and inspection authority for controlled substances, and adjust the scope of practice and prescribing authority for certain licensed health care professionals. It would also alter how hospitals and hospital pharmacies may dispense medications and how pharmacy-related rules are promulgated and enforced, while preserving existing controlled-substance law and professional prescribing authority.
The available record shows no committee transcript or recorded votes, so there is no direct evidence of floor or committee debate. Based on the bill text, the overall tone appears administrative and regulatory rather than ideological, with the bill aiming to update and clarify health care and controlled-substance statutes. The measure appears designed to streamline professional licensing and hospital pharmacy operations while maintaining oversight and public-safety controls.
The most likely points of contention are the bill’s changes to controlled-substance prescribing and hospital pharmacy authority. Potential concerns include the scope of authority given to advanced practice registered nurses, the limits on practitioners accepting unused controlled substances, and the balance of power between the Department of Health and Senior Services and the Board of Pharmacy over hospital pharmacy rules and inspections. Physician licensure provisions may also draw attention because they change qualification standards, background-check requirements, and waiver authority for out-of-state or nontraditional training pathways.